CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 21 enrolled
Drug / intervention
Oral micronized progesterone +1 moredrug
Likely dose
Oral micronized progesterone 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00632099
NCT00632099Phase 3Completed

Progesterone Treatment for Cocaine-dependent Women: A Pilot Study

New York State Psychiatric Institute·interventional·Posted Mar 10, 2008·Updated May 12, 2014

In Brief

A Phase 3 clinical trial evaluating Oral micronized progesterone and Placebo for Cocaine Dependence. Completed, enrolled 21 participants across 1 site.

Detailed Summary

The purpose of this pilot treatment trial is to evaluate the efficacy of oral micronized PROG in cocaine-dependent women. Since we have shown (Evans \& Foltin, 2006) that oral micronized PROG attenuates the positive subjective effects of smoked cocaine in females, but not in males, and we have preliminary data indicating that oral micronized PROG also reduces smoked cocaine self-administration in the laboratory, PROG appears to be an ideal potential candidate medication to evaluate in cocaine-dependent women. Prior to randomization to treatment, women will reside inpatient for one week to ensure cocaine abstinence since one of the primary outcome measures will be time to cocaine relapse.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 10, 2008
Enrollment StartFeb 1, 2008
Primary CompletionSep 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 18.3 years ago

Interventions

Oral micronized progesteronedrug

Oral micronized progesterone (up to 400 mg/day), suspended in olive oil

Placebodrug

matched placebo